Current Lung Injury News and Events

Current Lung Injury News and Events, Lung Injury News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
How reducing body temperature could help a tenth of all ICU patients
ROCKVILLE, MD - A tenth of all intensive care unit patients worldwide, and many critical patients with COVID-19, have acute respiratory distress syndrome (ARDS). (2021-02-23)

Whale Sharks show remarkable capacity to recover from injuries
A new study has for the first time explored the extraordinary rate at which the world's largest fish, the endangered whale shark, can recover from its injuries. The findings reveal that lacerations and abrasions, increasingly caused through collisions with boats, can heal in a matter of weeks and researchers found evidence of partially removed dorsal fins re-growing. (2021-02-23)

Scientists identify potential contributor to hyper immune responses in patients with severe COVID-19
Researchers have pinpointed a helper T cell population in the lungs of patients with severe COVID-19 that may be central to the development of hyperinflammation, lung injury, and subsequent acute respiratory distress syndrome (ARDS) during disease (2021-02-23)

New model helping identify pregnant women whose previous kidney injury puts them, babies at risk
Young pregnant women, who appear to have fully recovered from an acute injury that reduced their kidney function, have higher rates of significant problems like preeclampsia and low birthweight babies, problems which indicate their kidneys have not actually fully recovered. MCG scientists have developed a rodent model that is enabling studies to better understand, identify and ideally avoid this recently identified association. (2021-02-22)

Targeting the SARS-CoV-2 main protease yields promise in transgenic mouse model
Inhibitors based on approved drugs and designed to disrupt the SARS-CoV-2 viral protein Mpro display strong antiviral activity both in vitro and in a transgenic mouse model, a new study reports. (2021-02-18)

Cytoglobin: key player in preventing liver disease
Researchers have discovered that the use of Cytoglobin (CYGB) as an intravenous drug could delay liver fibrosis progression in mice. CYGB, discovered in 2001 by Professor Norifumi Kawada, is present in hepatic stellate cells, the cells that produce fibrotic molecules such as collagens when the liver has acute or chronic inflammation induced by different etiologies. The enhancement of CYGB on these cells or the injection of recombinant CYGB has the effect of suppressing liver damage and cirrhosis. (2021-02-16)

Army researchers expand study of ethics, artificial intelligence
The Army of the future will involve humans and autonomous machines working together to accomplish the mission. According to Army researchers, this vision will only succeed if artificial intelligence is perceived to be ethical. (2021-02-16)

Delayed medical treatment of high-impact injuries: A lesson from the Syrian civil war
Researchers report that patients injured in the facial bones by high-speed fire and operated on approximately 2-4 weeks after the injury suffered fewer post-operative complications compared to those wounded who underwent immediate surgical treatment. They hypothesize that this is due to a critical period of time before surgery, which facilitates healing and formation of new blood vessels in the area of the injury and, subsequently, an improvement in the blood and oxygen supply. (2021-02-16)

Researchers discover promising biomarkers to diagnose mild traumatic brain injury
Certain plasma microRNAs could serve as diagnostic biomarkers in mild traumatic brain injury, a new study from the University of Eastern Finland shows. The biomarkers were discovered in an animal model and they were successfully used also to diagnose mild traumatic brain injury in a subgroup of patients. (2021-02-15)

Researchers develop algorithm to find possible misdiagnosis
Researchers from the University of Copenhagen have developed an algorithm that can identify patients who may have been wrongly diagnosed. With the help of digital disease history, the algorithm is able to register disease trajectories that differ so much from normal trajectories that there may be a misdiagnosis. The algorithm has been developed on the basis of data from several hundreds of thousands of COPD patients. (2021-02-15)

Enormous ancient fish discovered by accident
Fossilised remains of a fish that grew as big as a great white shark and the largest of its type ever found have been discovered by accident. (2021-02-15)

Novel protein could reverse severe muscle wasting in disease, aging and trauma
Muscle stem cells drive the tissue's growth and repair after such injuries. But growing these cells in the lab and using them to therapeutically replace damaged muscle has been frustratingly difficult. Australian researchers have discovered a factor that triggers these muscle stem cells to proliferate and heal. In a mouse model of severe muscle damage, injections of this naturally occurring protein led to the complete regeneration of muscle and the return of normal movement after severe muscle trauma. (2021-02-10)

Lung ultrasound helps predict COVID-19 patient outcomes
Brazilian researchers applied an examination protocol based on an analysis of 12 lung regions to 180 severe patients and found that the higher the lung ultrasound score the greater the risk of ICU admission, intubation and death. (2021-02-10)

The genetic susceptibility of people with Down's syndrome to COVID-19
A study reveals the genetic factors that may expose or protect people with Down syndrome from SARS-CoV-2. TMPRSS2, a gene that codes for an enzyme critical for aiding the entry of SARS-CoV-2 in human cells, had 60% higher levels of expression in Down syndrome. The researchers also found higher expression levels for CXCL10, a gene that can trigger cytokine storms. The authors call to vaccinate people with Down syndrome against COVID-19 as a priority. (2021-02-08)

Bernese researchers create sophisticated lung-on-chip
In collaboration with clinical partners from the Inselspital, researchers from the ARTORG Center for Biomedical Research of the University of Bern have developed a second-generation lung-on-chip model with life-size dimension alveoli in a stretchable membrane, made of purely biological material. The new model reproduces key aspects of the lung tissue architecture not found in previous lungs-on-chip. This opens up new possibilities for basic pneumological research, understanding lung pathologies, drug screening and precision medicine. (2021-02-08)

Raised mortality from cardiac arrest in people with COVID-19
Sudden cardiac arrest is more often fatal in people with COVID-19, a new study shows. Those responsible for the research see the results as a wake-up call for the public and care providers alike. (2021-02-05)

COVID-19: Schools urgently need guidelines on improving ventilation in classrooms
There is an urgent need for guidelines on how schools can use ventilation to reduce the risk of COVID-19 transmission in the classroom, according to doctors at Imperial College London and the headteacher of a secondary school in Pinner, Middlesex. (2021-02-05)

Using Artificial Intelligence to prevent harm caused by immunotherapy
Until recently, researchers and oncologists had placed these lung cancer patients into two broad categories: those who would benefit from immunotherapy, and those who likely would not. Now, researchers at Case Western Reserve University, using artificial intelligence (AI) to analyze simple tissue scans, say they have discovered biomarkers that could tell doctors which lung cancer patients might actually get worse from immunotherapy. (2021-02-04)

Study examines role of biomarkers to evaluate kidney injury in cancer patients
A study by Mayo Clinic researchers published in Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells. (2021-02-03)

Study finds recommended ICU sedatives equally safe, effective
A study published today in the New England Journal of Medicine provides the most definitive evidence to date that, of the two drugs recommended for light sedation of patients receiving mechanical ventilation in the ICU, one is as effective and safe as the other. (2021-02-02)

Child head injury guidelines created
Australia's and New Zealand's first set of clinical guidelines for children's head injuries has been created. (2021-02-02)

Combining PD-1inhibitor with VEGF inhibitor in chemotherapy of cholangiocarcinoma patient
Cholangiocarcinoma is the second most frequent liver cancer. Many patients miss the opportunity of having a surgery performed on them and its control has always been considered difficult. Here, doctors from The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China, present a case of stage 4 cholangiocarcinoma. (2021-02-02)

Asian-relevant lung cancer research presented at Global Lung Cancer Conference hosted in Singapore
-Lung cancer continues to be the leading cause of cancer death in Singapore and the world. -The World Conference on Lung Cancer, the largest international gathering of clinicians, researchers and scientists in the field of lung cancer - with more than 6,000 participants - was held from 28 January to 31 January 2021 as a worldwide virtual event hosted by Singapore. -A group of Singapore clinicians and scientists presented new data to enhance understanding and treatment of lung cancer in the Asian population at the conference. (2021-02-01)

Patients with lung cancer reduce smoking rate after enrollment in phase III clinical trial
The first comprehensive, prospective study of smoking habits in patients with non-small cell lung cancer (NSCLC) who were enrolled in a phase III early-stage trial revealed that there was a high rate of smoking reduction and cessation following study entry, according to research published today in the Journal of Thoracic Oncology. (2021-02-01)

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore. (2021-01-31)

Host immune classifier HIC assays may predict treatment response
Using a host immune classifier (HIC) test for patients with non-small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore. (2021-01-30)

Nivolumab effective treatment for malignant mesothelioma
Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (2021-01-30)

Selected gene mRNA expression is not predictive of improved overall survival
)-- A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (2021-01-30)

LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate
Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer. (2021-01-30)

TALENT study supports NLCST and NELSON trial results
A study presented today by researchers with the Ministry of Health and Welfare in Taiwan confirmed the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker, high-risk population. The research was presented today at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer. (2021-01-30)

Two ADAURA analyses support use of Osimertinib for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer
Two presentations from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival (DFS) outcomes for patients with surgically resected non-small cell lung cancer (NSCLC) receiving osimertinib. The data were reported today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer (WCLC) Singapore. (2021-01-29)

Researchers probe new territory in treating patients with lung cancer during pandemic
On February 27, 2020, the flagship journal of the International Association for the Study of Lung Cancer, the Journal of Thoracic Oncology, published a case study that described two patients from Wuhan, China who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery. (2021-01-29)

Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 tumor proportion score of greater than or equal to 50% and no targetable EGFR or ALK aberrations. (2021-01-29)

Radiation Oncology trials using PET with FDG uptake among NSCLC patients
Two radiation oncology trials presented at the IALSC World Conference on Lung Cancer Singapore highlight how some researchers are exploring use of higher radiation boost doses to only PET-positive regions in locally-advanced non-small cell lung cancer (NSCLC). A previous large RTOG phase III trial revealed that the unform delivery of a high dose to the entire tumor led to poorer survival. (2021-01-29)

New treatment helps patients with a spinal cord injury
Spinal cord injuries disrupt the mechanism by which our bodies regulate blood pressure. A team of Swiss and Canadian scientists have developed a treatment that allows patients to regain control of their blood pressure, using targeted electrical spinal-cord stimulation. No medication is required. The team's findings were published today in Nature. (2021-01-28)

Sotorasib provides durable clinical benefit for patients with NSCLC and KRAS mutations
In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor KRAS p.G12C mutations, validating CodeBreak 100's phase I results, according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (2021-01-28)

Research finds blood pressure can be controlled without drugs after spinal cord injury
Canadian and Swiss researchers have created the first platform to understand the mechanisms underlying blood pressure instability after spinal cord injury. The discovery has led to a new cutting-edge solution. Spinal cord stimulators can bridge the body's autonomous regulation system, controlling blood pressure without medication. Findings are published in Nature. (2021-01-27)

Vaccine delivered via skin could help in fight against respiratory diseases
Brigham's Thomas Kupper, MD, and co-authors present results from preclinical studies suggesting skin scarification may help generate lung T cells and provide protection against infectious diseases, with implications for prevention of COVID-19. (2021-01-27)

Lung-MAP translational discoveries shared at 2020 World Conference on Lung Cancer
Investigators leading the Lung Cancer Master Protocol, or Lung-MAP trial, will present findings from three translational medicine studies at the 2020 World Conference on Lung Cancer, to be held online January 28-31, 2021. (2021-01-27)

Germline whole exome sequencing reveals the potential role of hereditary predisposition and therapeutic implications in small cell lung cancer, a tobacco-related cancer
A study presented today by Dr. Nobuyuki Takahashi of the Center for Cancer Research (CCR), National Cancer Institute (NCI), Bethesda, Md. at the IASLC World Conference on Lung Cancer Singapore demonstrates that small cell lung cancer (SCLC) may have an inherited predisposition and lays the foundation for understanding the interaction between genotype and tobacco exposure in exacerbating SCLC risk as well as potential therapeutic implications (2021-01-27)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.